Effects of high-dose soy isoflavones and equol on reproductive tissues in female cynomolgus monkeys

Biology of Reproduction

Volumn 75, Issue 3, 2006, Pages 477-486

  Wood, Charles E ^a   Appt, Susan E ^a   Clarkson, Thomas B ^a   Franke, Adrian A ^b   Lees, Cynthia J ^a   Doerge, Daniel R ^c   Mark Cline, J ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^c NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

Estradiol; Estrogen receptor; Female reproductive tract; Mammary glands; uterus

Indexed keywords

AGLYCONE; DAIDZEIN; EQUOL; ESTROGEN; GENISTEIN; ISOFLAVAN DERIVATIVE; ISOFLAVONE; ISOFLAVONOID; PROGESTERONE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOGENESIS; CANCER RISK; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOSE RESPONSE; ENDOMETRIUM; ESTROGEN ACTIVITY; FEMALE; FEMALE GENITAL SYSTEM; GENE EXPRESSION; GENE EXPRESSION REGULATION; MACACA; MAMMARY GLAND; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARIECTOMY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RACEMIC MIXTURE; SEXUAL DEVELOPMENT; SOYBEAN; UTERUS; UTERUS WEIGHT;

ANIMALS; CELL PROLIFERATION; DIET; ESTRONE; FEMALE; GENE EXPRESSION; GENITALIA, FEMALE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; ISOFLAVONES; MACACA FASCICULARIS; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, ANIMAL; MONOAMINE OXIDASE INHIBITORS; POSTMENOPAUSE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SOYBEANS; TUMOR MARKERS, BIOLOGICAL; UTERINE NEOPLASMS; UTERUS; VAGINA;

MACACA FASCICULARIS; PRIMATES; RODENTIA;

EID: 33747585809     PISSN: 00063363     EISSN: None     Source Type: Journal    
DOI: 10.1095/biolreprod.106.052142     Document Type: Article

References (62)

1. Mahady GB, Parrot J, Lee C, Yun GS, Dan A. Botanical dietary supplement use in peri- and postmenopausal women. Menopause 2003; 10:65-72.
2. Kurzer MS, Xu X. Dietary phytoestrogens. Annu Rev Nutr 1997; 17:353-381.
3. Setchell KDR. Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones. Am J Clin Nutr 1998; 68:1333S-1346S.
4. Martin PM, Horwitz KB, Ryan DS, McGuire WL. Phytoestrogen interaction with estrogen receptors in human breast cancer cells. Endocrinology 1978; 103:1860-1867.
5. Markiewics L, Garey J, Adlercreutz H, Gurpide E. In vitro bioassays of non-steroidal phytoestrogens. J Steroid Biochem Mol Biol 1993; 45:399-405.
6. Wang TT, Sathyamoorthy N, Phang JM. Molecular effects of genistein on estrogen receptor mediated pathways. Carcinogenesis 1996; 17:271-275.
7. Hsieh CY, Santell RC, Haslam SZ, Helferich WG. Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo. Cancer Res 1998; 58:3833-3838.
8. Ju YH, Allred CD, Allred KF, Karko KL, Doerge DR, Helferich WG. Physiological concentrations of dietary genistein dose-dependently stimulate growth of estrogen-dependent human breast cancer (MCF-7) tumors implanted in athymic nude mice. J Nutr 2001; 131:2957-2962.
9. Allred CD, Allred KF, Ju YH, Clausen LM, Doerge DR, Schantz SL, Korol DL, Wullig MA, Helferich WG. Dietary genistein results in larger MNU-induced, estrogen-dependent mammary tumors following ovariectomy of Sprague-Dawley rats. Carcinogenesis 2004; 25:211-218.
10. Tansey G, Hughes CL Jr, Cline JM, Krummer A, Walmer DK, Schmoltzer S. Effects of dietary soybean estrogens on the reproductive tract in female rats. Proc Soc Exp Biol Med 1998; 217:340-344.
11. Weiderpaxs E, Adami HO, Baron JA, Magnusxon C, Bergstrom R, Lindgren A, Correia N, Persson I. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999; 91:1131-1137.
12. Unfer V, Casini ML, Costabile L, Mignosa M, Gerli S, Di Renzo GC. Endometrial effects of long-term treatment with phytoestrogens: a randomized, double-blind, placebo-controlled study. Fertil Steril 2004; 82:145-148.
13. Petrakis NL, Barnes S, King EB, Lowenstein J, Wiencke J, Lee MM, Miike R, Kirk M, Coward L. Stimulatory influence of soy protein isolate on breast secretion in pre- and postmenopausal women. Cancer Epidemiol Biomarkers Prev 1996; 5:785-794.
14. Hargreaves DF, Potten CS, Harding C, Shaw LE, Morton MS, Roberts SA, Howell A, Bundred NJ. Two-week dietary soy supplementation has an estrogenic effect on normal premenopausal breast. J Clin Endocrinol Metab 1999; 84:4017-4024.
15. Nikander E, Rutanen EM, Nieminen P, Wahlstrom T, Ylikorkala O, Tiitinen A. Lack of effect of isoflavonoids on the vagina and endometrium in postmenopausal women. Fertil Steril 2005; 83:137-42.
16. Duncan AM, Underhill KE, Xu X, Lavalleur J, Phipps WR, Kurzer MS. Modest hormonal effects of soy isoflavones in postmenopausal women. J Clin Endocrinol Metab 1999; 84:3479-3484.
17. Kaari C, Haidar MA, Junior JM, Nunes MG, Quadros LG, Kemp C, Stavale JN, Baracat EC. Randomized clinical trial comparing conjugated equine estrogens and isoflavones in postmenopausal women: a pilot study. Maturitas 2006; 10:53:49-58.
18. Balk JL, Whiteside DA, Naus G, DeFerrari E, Roberts JM. A pilot study of the effects of phytoestrogen supplementation on postmenopausal endometrium. J Soc Gynecol Investig 2002; 9:238-242.
19. Upmalis DH, Lobo R, Bradley L, Warren M, Cone FL, Lamia CA. Vasomotor symptom relief by soy isoflavone extract tablets in postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study. Menopause 2000; 7:236-42.
20. Mahady GB. Do soy isoflavones cause endometrial hyperplasia? Nutr Rev 2005; 63:392-397.
21. Maskarinec G, Takata Y, Franke AA, Williams AE, Murphy SP. A 2-year soy intervention in premenopausal women does not change mammographic densities. J Nutr 2004; 134:3089-3094.
22. Goodman MT, Wilkens LR, Hankin JH, Lyu LC, Wu AH, Kolonel LN. Association of soy and fiber consumption with the risk of endometrial cancer. Am J Epidemiol 1997; 146:294-306.
23. Trock BJ, Hilakivi-Clarke L, Clarke R. Meta-analysis of soy intake and breast cancer risk. J Natl Cancer Inst 2006; 98:459-471.
24. Badger TM, Ronis MJ, Simmen RC, Simmen FA. Soy protein isolate and protection against cancer. J Am Coll Nutr 2005; 24:S146-S149.
25. Ingram D, Sanders K, Kolybaba M, Lopez. D. Case-control study of phytooestrogens and breast cancer. Lancet 1997; 350:990-994.
26. Zheng W, Dai Q, Custer LJ, Shu XO, Wen WQ, Jin F, Franke AA. Urinary excretion of isoflavones and the risk of breast cancer. Cancer Epidemiol Biomark Prev 1999; 8:35-40.
27. Dai Q, Franke AA, Jin F, Shu XO, Hebert JR, Custer LJ, Cheng J, Gao YT, Zheng W. Urinary excretion of phytoestrogens and risk of breast cancer among Chinese women in Shanghai. Cancer Epidemiol Biomark Prev 2002; 11:815-823.
28. Wood CE, Register TC, Franke AA, Anthony MS, Cline JM. Dietary soy isoflavones inhibit estrogen effects in the postmenopausal breast. Cancer Res 2006; 66:1241-1249.
29. Wood CE, Register TC, Anthony MS, Kock ND, Cline JM. Breast and uterine effects of soy isoflavones and conjugated equine estrogens in postmenopausal female monkeys. J Clin Endocrinol Metab 2004; 89:3462-3468.
30. Foth D, Cline JM. Effects of mammalian and plant estrogens on mammary glands and uteri of macaques. Am J Clin Nutr 1998; 68:S1413-S1417.
31. Setchell KDR, Brown NM, Lydeking-Olsen E. The clinical importance of the metabolite equol-H clue to the effectiveness of soy and its isoflavones. J Nutr 2002; 132:3577-3584.
32. Muthyala RS, Ju YH, Sheng S, Williams LD, Doerge DR, Katzenellenbogen BS, Helferich WG, Katzenellenbogen JA. Equol, a natural estrogenic metabolite from soy isoflavones: convenient preparation and resolution of R- and S-equols and their differing binding and biological activity through estrogen receptors alpha and beta. Bioorg Med Chem 2004; 12:1559-1567.
33. Tang BY, Adams NK. Effect of equol on oestrogen receptors and on synthesis of DNA and protein in the immature rat uterus. J Endocrinol 1980; 5:291-297.
34. Lehmann L, Esch HL, Wagner J, Rohnstock L, Metzler M. Estrogenic and genotoxic potential of equol and two hydroxylated metabolites of Daidzein in cultured human Ishikawa cells. Toxicol Lett 2005; 158:72-86.
35. Selvaraj V, Zakroczymski MA, Naaz A, Mukai M, Ju YH, Doerge DR, Katzenellenbogen JA, Helferich WG, Cooke PS. Estrogenicity of the isoflavone metabolite equol on reproductive and non-reproductive organs in mice. Biol Reprod 2004; 71:966-972.
36. Frankenfeld CL, McTieman A, Aiello EJ, Thomas WK, LuCroix K, Schranm J, Schwartz SM, Holt VL, Lampe JW. Mammographic density in relation to daidzein-metabolizing phenotypes in overweight, postmenopausal women. Cancer Epidemiol Biomarkers Prev 2004; 13:1156-1162.
37. Duncan AM, Merz-Demlow BE, Xu X, Phipps WR, Kurzer MS. Premenopausal equol excretors show plasma hormone profiles associated with lowered risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2000; 9:581-586.
38. Nettleton JA, Greany KA, Thomas W, Wangen KE, Adlercreutz H, Kurzer MS. The effect of soy consumption on the urinary 2:16-hydroxyestrone ratio in postmenopausal women depends on equol production status but is not influenced by probiotic consumption. J Nutr 2005; 135:603-608.
39. Setchell KD, Clerici C, Lephart ED, Cole SJ, Heenan C, Castellani D, Wolfe BE, Nechemius-Zimmer L, Brown NM, Lund TD, Handa RJ, Heubi JE. S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr 2005; 81:1072-1079.
40. Harris PF, Remington PL, Tremham-Dietz A, Allen CI, Newcomb PA. Prevalence and treatment of menopausal symptoms among breast cancer survivors. J Pain Symptom Manage 2002; 23:501-509.
41. Wood CE, Barnes S, Cline JM. Phytoestrogen actions in the breast and uterus. In: Gilani GS, Anderson JJB, (eds.), Phytoestrogens and Health, 1st ed. Champaign: AOCS Press; 2002:440-469.
42. Magness CL, Fellin PC, Thomas MJ, Korth MJ, Agy MB, Proll SC, Fitzgibbon M, Scherer CA, Miner DG, Katze MG, Iadonato SP. Analysis of the Macaca mulatta transcriptome and the sequence divergence between Macara and human. Genome Biol 2005; 6:R60.
43. Pavlicek A, Noskov VN, Kouprina N, Barrett JC, Jurka J, Larionov V. Evolution of the tumor suppressor BRCA1 locus in primates: implications for cancer predisposition. Hum Mol Genet 2004; 13:2737-2751.
44. Cline JM, Soderqvist G, Register TC, Williams JK, Adams MR, Von Schoultz B. Assessment of hormonally active agents in the reproductive tract of female nonhuman primates. Toxicol Pathol 2001; 29:84-90.
45. Cline JM, Soderqvist G, von Schoultz E, Skoog L, von Schoultz B. Effects of conjugated estrogens, medroxyprogesterone acetate, and tamoxifen on the mammary glands of macaques. Breast Cancer Res Treat 1998; 48:221-229.
46. Dimitrakakis C, Zhou J, Wang J, Belanger A, LuBric F, Cheng C, Powell D, Bondy C. A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause 2003; 10:292-298.
47. Schneider K, Oltmanns J, Hassauer M. Allometric principles for interspecies extrapolation in toxicological risk assessment-empirical investigations. Regul Toxicol Pharmacol 2004; 39:334-347.
48. Blair RM, Appt SE, Franke AA, Clarkson TB. Treatment with antibiotics reduces plasma equol concentration in cynomolgus monkeys (Macaca fascicularis). J Nutr 2003; 133:2262-2267.
49. Berry M, Nunez AM, Chambon P. Estrogen-responsive element of the human pS2 gene is an imperfectly palindromic sequence. Proc Natl Acad Sci U S A 1989; 86:1218-1222.
50. Petz LN, Ziegler YS, Schultz JR, Nardulli AM. Fos and Jun inhibit estrogen-induced transcription of the human progesterone receptor gene through an activator protein-1 site. Mol Endocrinol 2004; 18:521-532.
51. Hall JM, Korach KS. Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells. Mol Endocrinol 2003; 17:792-803.
52. Key T, Appleby P, Barnes I, Reeves G. Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002; 94:606-616.
53. Arai Y, Uehara M, Sato Y, Kimira M, Eboshida A, Adlercreutz H, Watanabe S. Comparison of isoflavones among dietary intake, plasma concentration and urinary excretion for accurate estimation of phytoestrogen intake. J Epidemiol 2000; 10:127-135.
54. Morton MS, Arisaka O, Miyake N, Morgan LD, Evans BA. Phytoestrogen concentrations in serum from Japanese men and women over forty yean of age. J Nutr 2002; 132:3168-3171.
55. Clarkson TB, Appt SE, Wood CE, Cline JM. Lessons to be learned from animal studies on hormones and the breast. Maturitas 2004; 49:79-89.
56. Balk E, Chung M, Chew P, Ip S, Raman G, Kupelnick B, Tatsioni A, Sun Y, Devine D, Lau J. Effects of soy on health outcomes. Evid Rep Technol Assess (Summ) 2005; 126:1-8.
57. Ju YH, Fultz J, Allied KF, Doerge DR, Helferich WG. Effects of dietary daidzein and its metabolite, equol, at physiological concentrations on the growth of estrogen-dependent human breast cancer (MCF-7) tumors implanted in ovariectomized athymic mice. Carcinogenesis 2006; 27:856-863.
58. Lamartiniere CA, Wang J, Smith-Johnson M, Eltoum IE. Daidzein: bioavailability, potential for reproductive toxicity, and breast cancer chemoprevention in female rats. Toxicol Sci 2002; 65:228-238.
59. Chang HC, Churchwell MI, Delclos KB, Newbold RR, Doerge DR. Mass spectrometric determination of Genistein tissue distribution in diet-exposed Sprague-Dawley rats. J Nutr 2000; 130:1963-1970.
60. Picherit C, Chanteranne B, Bennetau-Pelissero C, Davicco MJ, Lebecque P, Barlet JP, Coxam V. Dose-dependent bone-sparing effects of dietary isoflavones in the ovariectomised rat. Br J Nutr 2001; 85:307-316.
61. Murrill WB, Brown NM, Zhang JX, Manzolillo PA, Barnes S, Lamartiniere CA. Prepubertal genistein exposure suppresses mammary cancer and enhances gland differentiation in rats. Carcinogenesis 1996; 17:1451-1457.
62. van Weerden WM, Bierings HG, van Steenbrugge GJ, de Jong FH, Schroder FH. Adrenal glands of mouse and rat do not synthesize androgens. Life Sci 1992; 50:857-861.